For how we live.
The REACT study imaged people aged 18 to 70 with no known cardiovascular disease. Atherosclerosis was already present in some people in their twenties, and it was usually in the legs, not the heart.
PRESC1SE-MI covered 67,624 chest-pain presentations at 19 hospitals. The one-hour troponin pathway matched the three-hour one on safety, and median length of stay was identical: 309 minutes.
The ESC released updated heart failure guidance plus first-ever guidelines on cardiac rehabilitation and on cardiovascular disease with chronic kidney disease. All three sit behind a paywall.
SWITCH-SWEDEHEART randomised regions rather than patients. Over 17,095 people, a default prasugrel policy did not lower ischaemic events against ticagrelor, but major bleeding was lower.
DANISH-CRT randomised 1,000 patients to electrically targeted or conventional left ventricular lead placement. After nearly four years, death and heart failure admissions were the same.
PRAGUE-26 randomised 558 patients across 11 Czech hospitals. The seven-day composite fell from 6.8% to 0.7%, driven by cardiorespiratory collapse, with no clear bleeding penalty.
PREMIUM tested prasugrel alone against aspirin plus prasugrel in 2,216 STEMI patients in Japan. Monotherapy failed to show noninferiority, and the confidence interval sat above one.
POET II randomised 508 stabilised patients to stop antibiotics or complete the standard course. The safety endpoint met noninferiority; relapse of infection did not go the same way.
The Fifth Universal Definition of Myocardial Infarction drops the numbered types, keeps sex-specific troponin thresholds, and proposes ICD-11 codes so the categories can be counted.
ABYSS and SMART-DECISION together cover 6,238 stable patients. Discontinuation cleared both noninferiority margins, though the authors say the primary endpoint's composition limits what it shows.
CARDIO-TTRansform randomised 1,432 patients with transthyretin amyloid cardiomyopathy to eplontersen or placebo for 140 weeks. The confidence interval around the primary result crosses one.
Guidelines have hedged on anticoagulation for people with one stroke risk factor. SINGLE-AF randomised 1,803 patients in South Korea, and the events it counted were very few in both arms.
ACACIA-HCM met both primary endpoints in symptomatic non-obstructive HCM. The gains were real but small, and one in ten patients had a reversible drop in pumping function.